Last reviewed · How we verify
Shalvata Mental Health Center — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Ketamine (1st phase) | Ketamine (1st phase) | marketed | NMDA receptor antagonist | NMDA receptor | Psychiatry / Mental Health | |
| Ketamine (2st phase) | Ketamine (2st phase) | marketed | NMDA receptor antagonist | NMDA receptor | Psychiatry, Anesthesia, Pain Management |
Therapeutic area mix
- Psychiatry / Mental Health · 1
- Psychiatry, Anesthesia, Pain Management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ajou University School of Medicine · 1 shared drug class
- Alameda Health System · 1 shared drug class
- American University of Beirut Medical Center · 1 shared drug class
- Asker & Baerum Hospital · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Auris Medical AG · 1 shared drug class
- Beijing Tiantan Hospital · 1 shared drug class
- Acacia Pharma Ltd · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Shalvata Mental Health Center:
- Shalvata Mental Health Center pipeline updates — RSS
- Shalvata Mental Health Center pipeline updates — Atom
- Shalvata Mental Health Center pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Shalvata Mental Health Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shalvata-mental-health-center. Accessed 2026-05-17.